Document is current
Any future updates will be listed below
-
Authors
Bazazi, Alexander R.
Culbert, Gabriel J.
Wegman, Martin P.
Heimer, Robert
Kamarulzaman, Adeeba
Altice, Frederick L.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02396979 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
https://doi.org/10.1186/s12879-022-07804-6
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (F30DA039716, K23DA041988, R01DA025943)
National Institute of Mental Health (R25MH060482, F30MH105153)
National Institute of General Medical Sciences (T32GM07205)
Universiti Malaya (High Impact Research Grant UM.C/625/1/HIR/MOHE/MED01)
- License Information
-
More Information
Article History
Received: 5 November 2021
Accepted: 6 June 2022
First Online: 11 November 2022
Declarations
:
: Informed consent was obtained from all study participants prior to enrollment and was repeated after prison release. Participants consented to collection of medical and administrative records in advance. This study was approved by institutional review boards at Yale University, University Malaya Medical Centre, and the Office of Human Research Protection at the U.S. Department of Health and Human Services (Protocol #2000023124). All methods were performed in accordance with the approved protocol and the Declaration of Helsinki.
: Not applicable.
: FLA reports Speakers Bureau: Simply Speaking HIV, Gilead Sciences, Merck, Clinical Care Options (role: speaker); Grants: NIH, NIDA, HRSA, SAMHSA, Gilead Foundation (role: PI); Advisory Board: Merck, Gilead (role: member/consultant). None these conflicts are related to this research. ARB, GJC, MPW, RH, and AK have no competing interests to declare.
